Auxilium Pharmaceuticals Lowered to “Neutral” at R. F. Lafferty (AUXL)
Auxilium Pharmaceuticals (NASDAQ:AUXL) was downgraded by research analysts at R. F. Lafferty from a “buy” rating to a “neutral” rating in a report released on Monday, Stock Ratings Network reports.
A number of other analysts have also recently weighed in on AUXL. Analysts at Zacks reiterated a “neutral” rating on shares of Auxilium Pharmaceuticals in a research note to investors on Thursday, September 26th. They now have a $19.00 price target on the stock. Separately, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Auxilium Pharmaceuticals in a research note to investors on Tuesday, September 17th. They set a “buy” rating on the stock. Finally, analysts at MKM Partners upgraded shares of Auxilium Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note to investors on Tuesday, September 10th. They now have a $22.00 price target on the stock, up previously from $17.00. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $22.46.
Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) traded down 1.91% during mid-day trading on Monday, hitting $16.98. 272,878 shares of the company’s stock traded hands. Auxilium Pharmaceuticals has a 52-week low of $13.87 and a 52-week high of $22.47. The stock has a 50-day moving average of $18.0 and a 200-day moving average of $17.07. The company has a market cap of $837.0 million and a P/E ratio of 6.63.
Auxilium Pharmaceuticals (NASDAQ:AUXL) last released its earnings data on Thursday, August 1st. The company reported $0.02 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.03) by $0.05. The company had revenue of $100.50 million for the quarter, compared to the consensus estimate of $91.43 million. During the same quarter last year, the company posted $0.16 earnings per share. Auxilium Pharmaceuticals’s revenue was up 28.5% compared to the same quarter last year. On average, analysts predict that Auxilium Pharmaceuticals will post $0.52 earnings per share for the current fiscal year.
Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.